Result:Weak· Market: Down#Margin squeeze
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 44.88 | 49.9% | 4.0% |
| Total Income | 47.78 | 47.0% | 4.5% |
| Expenditure | 43.91 | 37.2% | 3.9% |
| PBT | 3.86 | 80.9% | 12.0% |
| Net Profit | 1.97 | 86.8% | 13.0% |
| OPM | 6.54% | 18.17pp | 1.03pp |
| NPM | 4.12% | 12.40pp | 0.83pp |
| EPS | 0.83 | 80.4% | 55.9% |
Pharma core-profit metric fell -13% YoY on tepid 4% revenue growth with both OPM (7.6%→6.5%) and NPM (5.0%→4.1%) compressing, marking a below-par quarter.
Informational and educational content only. Not investment advice.